http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-074485-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84bf3df3c637864eb72d38d2bb2eee7a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-64 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 |
| filingDate | 2009-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4bd84f34c1e3b675e4d5f66e949c93b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1adb2b9bc68dd51a6bd4a4488968302a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8561704fd7be5df9dbdb8500265b8d25 |
| publicationDate | 2011-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-074485-A1 |
| titleOfInvention | VACCINE AGAINST NEOPLASIC OR CANCEROSE INJURIES CAUSED BY THE HUMAN PAPILOMA VIRUS (HPV), PROCEDURES, USES AND METHODS |
| abstract | Vaccines against neoplastic or cancerous lesions caused by the papillomavirus (HPV) comprising spherical particles of the E7 peptide of the papillomavirus and optionally an adjuvant, where the spherical particles can be oligomeric. The oligomeric spherical particles can have a diameter of about 50 nm and a molecular weight of about 700 kDa. The vaccine may be useful for preventing and / or treating papillomavirus (HPV) associated lesions. Claim 6: The vaccine according to claim 2, characterized in that the adjuvant is the monophosphoryl 3-deacylated lipid A (MPL). Claim 7: The vaccine according to claim 2, characterized in that the adjuvant is ODN2006. Claim 8: The vaccine according to claim 1, characterized in that the spherical particles have repetitive beta-leaf structures, amyloid-like. Claim 9: The vaccine according to claim 1, characterized in that the spherical particles comprise between 2 and 100 monomers of the E7 peptide. Claim 12: A method for stabilizing spherical particles, characterized in that it comprises a controlled oxidation of said particles. |
| priorityDate | 2009-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25200834 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419565228 |
Total number of triples: 26.